AbstractsStrattmont Group2024-02-02T16:38:17-05:00 ASCO abstracts 2015 thru present6/5/2022: Phase I clinical trial of NEO-201, an anti-tumor-associated CEACAM-5/6 monoclonal antibody in solid tumors1/23/2020: Phase I with expansion cohorts in a study of NEO-201 in adults with chemo-resistant solid tumors2/7/2020: Indirect mechanisms of action of a novel IgG1 monoclonal antibody, NEO-201, to enhance immune killing of tumor 6/1/2019: Phase 1 with expansion cohorts in a study of NEO-201 in adults with chemo-resistant solid tumors 6/5/2017: Ensituximab (E) in patients (pts) with refractory metastatic colorectal cancer (mCRC): Results of a phase I/II clinical trial 6/5/2015: A phase 2 study of NEO-102 (ensituximab), a novel chimeric monoclonal antibody, in adult patients (pts) with unresectable, metastatic colorectal cancer (mCRC) 6/2/2015: A phase II multicenter study of the chimeric monoclonal antibody NEO102 (N) in adults with refractory colorectal cancer (CC) 1/23/2015: A phase II therapeutic, open label, multi-center clinical trial of NPC-1C, a chimeric monoclonal antibody(mAb), in adults with chemotherapy refractory metastatic colorectal cancer (mCRC), initial results 1/16/2015: A phase I/II multicenter study of the chimeric monoclonal antibody NEO102 (NPC-1C) in adults with refractory pancreatic (PC) and colorectal cancer (CC) AACR abstracts 2015 through present 11/20/2023: The rationale for the combination of the monoclonal antibody NEO-201 with Immune Checkpoint Inhibitors (ICI) 9/22/2023: The anti-core 1 O-glycans targeting monoclonal antibody NEO-201 recognizes and reduces the quantity of naïve regulatory T cells in PBMCs of cancer patients (See abstract number P137 of the linked pdf file) 4/18/2023: A therapeutic humanized anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target human granulocytic myeloid-derived suppressor cells (gMDSCs) and regulatory T (Tregs) cells | Abstract 9/15/2022: A multicenter randomized phase II study of gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel with a MUC5AC antibody (NPC-1C) in advanced pancreatic cancer 4/9/2022: Targeting variant of CEACAM5 and CEACAM6 using NEO-201 and IL-15 in gynecologic cancers 8/15/2020: A therapeutic humanized anti-carcinoma monoclonal antibody (mAb) can enhance NK activity and target immunosuppressive regulatory T cells 4/25/2020: Activating innate immune response as strategy for endometrial cancer treatment 7/1/2019: Abstract 3947: Mechanisms of action of a neoantigen-targeting antibody NEO-201 7/1/2018: Abstract 3821: The neoantigen-targeting antibody NEO-201 enhances NK cell-dependent killing of tumor cells through blockade of the inhibitory CEACAM5/CEACAM1 immune checkpoint pathway 7/1/2018: Abstract 619: ALT-803 enhances antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by NEO-201 against human carcinoma cells 7/1/2017: Abstract 3025: Preclinical characterization of a novel monoclonal antibody targeting a neo-antigen expressed in ovarian and GI malignancies 7/1/2016: Abstract 1496: Identification of target and cytotoxicity of novel monoclonal antibody NEO-201 in ovarian and uterine cancer subtypes SITC abstracts 2015 through present 11/3/2023: Post-treatment neutrophil-to-lymphocyte ratio and gMDSCs as independent prognostic factors for treatment efficacy with monoclonal antibody NEO-201 and pembrolizumab 11/10/2022: PHASE IIA COMBINING NEO-201 WITH PEMBROLIZUMAB IN ADULTS WITH CHEMO-RESISTANT SOLID TUMORS11/10/2022: IDENTIFICATION OF THE O-GLYCAN EPITOPE TARGETED BY AN ANTI-HUMAN CARCINOMA MONOCLONAL ANTIBODY (MAB) NEO-20111/12/2021: AN ANTI-CARCINOMA MONOCLONAL ANTIBODY (MAB) NEO-201 CAN ALSO TARGET HUMAN ACUTE MYELOID LEUKEMIA (AML) CELL LINES IN VITRO 11/12/2021: A THERAPEUTIC HUMANIZED ANTI-CARCINOMA MONOCLONAL ANTIBODY (MAB) CAN ALSO IDENTIFY IMMUNOSUPPRESSIVE REGULATORY T (TREGS) CELLS AND DOWN REGULATE TREG-MEDIATED IMMUNOSUPPRESSION 11/8/2019: An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target and eliminate human immunosuppressive regulatory T cells | Abstract Other abstracts 2019 through present12/14/23: The rationale for the combination of the monoclonal antibody NEO-201 with Immune Checkpoint Inhibitors (ICI)
